| Browse All

Alvotech (ALVO)

Healthcare | Drug Manufacturers - Specialty & Generic | Luxembourg, Luxembourg | NasdaqGM
3.61 USD -0.01 (-0.276%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 3.61

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 11:39 p.m. EDT

Alvotech presents a severe short-term short signal driven by significant negative momentum (trading at 52-week lows), heavy legal scrutiny regarding a massive price crash, and deteriorating sentiment evidenced by the news flow. Long-term prospects are rated a zero due to critical structural red flags: negative book value (confirming the biosimilar patent cliff risks), negative operating cash flow, and severe analyst skepticism with reversed target prices. There is no dividend, classifying it as a 0/0/0 scenario with no investment edge.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.248224
AutoETS0.282177
AutoTheta0.282208
MSTL0.286909

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 43%
H-stat 14.29
Ljung-Box p 0.000
Jarque-Bera p 0.198
Excess Kurtosis -0.85
Attribute Value
Sector Healthcare
Revenue per Share 2.033
Market Cap 1,126,494,336
Trailing P/E 36.10
Forward P/E 19.73
Beta 0.25
Profit Margins 4.74%
Website https://www.alvotech.com

Info Dump

Attribute Value
52 Week Change -0.56662667
Address1 9, Rue de Bitbourg
All Time High 18.0
All Time Low 3.03
Ask 3.69
Ask Size 3
Average Analyst Rating 2.0 - Buy
Average Daily Volume10 Day 326,910
Average Daily Volume3 Month 525,145
Average Volume 525,145
Average Volume10Days 326,910
Beta 0.246
Bid 3.54
Bid Size 3
Book Value -0.912
City Luxembourg
Compensation As Of Epoch Date 1,767,139,200
Country Luxembourg
Crypto Tradeable 0
Currency USD
Current Price 3.61
Current Ratio 1.888
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.7492
Day Low 3.6
Earnings Call Timestamp End 1,778,155,200
Earnings Call Timestamp Start 1,778,155,200
Earnings Timestamp 1,778,097,600
Earnings Timestamp End 1,778,097,600
Earnings Timestamp Start 1,778,097,600
Ebitda 103,981,000
Ebitda Margins 0.17657
Enterprise To Ebitda 23.112
Enterprise To Revenue 4.081
Enterprise Value 2,403,183,104
Eps Current Year 0.0063
Eps Forward 0.18295
Eps Trailing Twelve Months 0.1
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.9108
Fifty Day Average Change -0.30080009
Fifty Day Average Change Percent -0.076915234
Fifty Two Week Change Percent -56.662666
Fifty Two Week High 11.85
Fifty Two Week High Change -8.240001
Fifty Two Week High Change Percent -0.6953587
Fifty Two Week Low 3.03
Fifty Two Week Low Change 0.5799999
Fifty Two Week Low Change Percent 0.19141912
Fifty Two Week Range 3.03 - 11.85
Financial Currency USD
First Trade Date Milliseconds 1,655,386,200,000
Float Shares 114,087,496
Forward Eps 0.18295
Forward P E 19.732166
Free Cashflow 24,599,624
Full Exchange Name NasdaqGM
Full Time Employees 1,279
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.60001
Gross Profits 353,345,984
Has Pre Post Market Data 1
Held Percent Insiders 0.62566
Held Percent Institutions 0.06064
Implied Shares Outstanding 312,048,292
Industry Drug Manufacturers - Specialty & Generic
Industry Disp Drug Manufacturers - Specialty & Generic
Industry Key drug-manufacturers-specialty-generic
Ipo Expected Date 2,022-06-16
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Long Name Alvotech
Market us_market
Market Cap 1,126,494,336
Market State CLOSED
Max Age 86,400
Message Board Id finmb_693209405
Most Recent Quarter 1,767,139,200
Net Income To Common 27,919,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,124,934,092
Number Of Analyst Opinions 6
Open 3.65
Operating Cashflow -50,197,000
Operating Margins 0.33841
Payout Ratio 0.0
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 3.61
Post Market Time 1,776,456,604
Previous Close 3.62
Price Eps Current Year 573.01587
Price Hint 4
Price To Book -3.9583333
Price To Sales Trailing12 Months 1.9128659
Profit Margins 0.04741
Quick Ratio 1.014
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 2.0
Region US
Regular Market Change -0.00999999
Regular Market Change Percent -0.27624285
Regular Market Day High 3.7492
Regular Market Day Low 3.6
Regular Market Day Range 3.6 - 3.7492
Regular Market Open 3.65
Regular Market Previous Close 3.62
Regular Market Price 3.61
Regular Market Time 1,776,456,001
Regular Market Volume 202,980
Return On Assets 0.03822
Revenue Growth 0.101
Revenue Per Share 2.033
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 312,048,292
Shares Percent Shares Out 0.0095999995
Shares Short 3,000,511
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 2,961,422
Short Name Alvotech
Short Percent Of Float 0.025899999
Short Ratio 4.37
Source Interval 15
Symbol ALVO
Target High Price 50.0
Target Low Price 4.0
Target Mean Price 13.83333
Target Median Price 7.5
Total Cash 172,359,008
Total Cash Per Share 0.552
Total Debt 1,449,144,960
Total Revenue 588,904,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.1
Trailing P E 36.1
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.2613
Two Hundred Day Average Change -2.6513002
Two Hundred Day Average Change Percent -0.42344245
Type Disp Equity
Volume 202,980
Website https://www.alvotech.com
Zip 1,273